Validation of ANG-1 and P-SEL as biomarkers of post-COVID-19 conditions using data from the Biobanque québécoise de la COVID-19, 2023, Rousseau+

Discussion in 'Long Covid research' started by EndME, Oct 25, 2023.

  1. EndME

    EndME Senior Member (Voting Rights)

    Messages:
    1,195
    Validation of ANG-1 and P-SEL as biomarkers of post-COVID-19 conditions using data from the Biobanque québécoise de la COVID-19 (BQC-19)

    The quest for understanding and managing the long-term effects of COVID-19, often referred to as Long COVID or post-COVID-19 condition (PCC), remains an active research area. Recent findings highlighted angiopoietin-1 (ANG-1) and p-selectin (P-SEL) as potential diagnostic markers, but validation is essential, given the inconsistency in COVID-19 biomarker studies. Leveraging the biobanque québécoise de la COVID-19 (BQC19) biobank, we analyzed the data of 249 participants.

    Both ANG-1 and P-SEL levels were significantly higher in patients with PCC participants compared with control subjects at 3 months using the Mann-Whitney U test.

    We managed to reproduce and validate the findings, emphasizing the importance of collaborative biobanking efforts in enhancing the reproducibility and credibility of Long COVID research outcomes.


    https://clinicalproteomicsjournal.biomedcentral.com/articles/10.1186/s12014-023-09436-7
     
    Hutan, LarsSG and cassava7 like this.
  2. EndME

    EndME Senior Member (Voting Rights)

    Messages:
    1,195
    Validating some of the findings of Douglas Frasers team whose work and choice of cohort (predominantly older, a slight majority of males, often with pre-existing conditions, with predominantly respiratory and coughing problems) has been discussed here:
    The interesting question now will be how exactly the validation cohort looks like and which markers correlate with which subgroup of that validation cohort.
     
  3. LarsSG

    LarsSG Senior Member (Voting Rights)

    Messages:
    370
    They really don't give you much with only a median and Mann-Whitney values, but it does look like something.

    I guess what's needed now is to repeat this in another chronic illness control group, to see if this is meaningfully about LC or just a general marker of illness.
     
    Hutan likes this.
  4. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,317
    Location:
    Aotearoa New Zealand
    The control cohort is also post-infection.
    The PCC cohort here has fewer people over 65 (18%) than the control cohort (25%).
    Also 59% female versus only 46% female in the control cohort
    Still a high hospitalisation rate compared to the controls (58% versus 34%), although it is claimed that 55% of the PCC cohort had a mild acute illness. 69% of the control cohort had a mild acute illness.

    So, there is still some doubt about whether the ANG-1 and P-SEL measures might have something to do with increased illness severity rather than PCC/Long Covid. But the findings seem resilient to the sex and age characteristics of the cohorts.
     
    Last edited: Oct 31, 2023
    SNT Gatchaman and EndME like this.
  5. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,317
    Location:
    Aotearoa New Zealand
    The reported persisting symptoms seem quite odd - the percentages reporting each were mostly much lower than I'm used to seeing in Long Covid cohorts.
    49.7% reported fatigue; 33.1% reported breathlessness; 20.1% reported joint pain. 41% reported 'anxiety and depression'; loss of taste and smell 20.9%.
     
    Last edited: Oct 31, 2023
    EndME likes this.

Share This Page